Cerevel Therapeutics Holdings Inc (CERE)
42.10
-0.25
(-0.59%)
USD |
NASDAQ |
May 17, 16:00
42.10
0.00 (0.00%)
After-Hours: 20:00
Cerevel Therapeutics Holdings Research and Development Expense (Quarterly): 106.42M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 106.42M |
| December 31, 2023 | 97.13M |
| September 30, 2023 | 85.25M |
| June 30, 2023 | 74.08M |
| March 31, 2023 | 78.18M |
| December 31, 2022 | 81.31M |
| September 30, 2022 | 71.38M |
| June 30, 2022 | 72.54M |
| March 31, 2022 | 55.02M |
| Date | Value |
|---|---|
| December 31, 2021 | 47.84M |
| September 30, 2021 | 40.16M |
| June 30, 2021 | 37.29M |
| March 31, 2021 | 36.56M |
| December 31, 2020 | 30.14M |
| September 30, 2020 | 24.03M |
| June 30, 2020 | 22.18M |
| March 31, 2020 | 26.96M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
22.18M
Minimum
Jun 2020
106.42M
Maximum
Mar 2024
58.03M
Average
55.02M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| AbbVie Inc | 1.939B |
| Bristol-Myers Squibb Co | 2.695B |
| Madrigal Pharmaceuticals Inc | 71.24M |
| Viking Therapeutics Inc | 24.10M |
| Karuna Therapeutics Inc (DELISTED) | 82.19M |